Pimecrolimus 1% cream for cutaneous lupus erythematosus

J Am Acad Dermatol. 2004 Sep;51(3):407-10. doi: 10.1016/j.jaad.2004.01.044.


Topical treatment of cutaneous lupus erythematosus usually includes potent glucocorticosteroids. However, prolonged use causes adverse side effects including skin atrophy as the foremost concern. In contrast to glucocorticosteroids, the anti-inflammatory and immunosuppressive macrolactam pimecrolimus has no atrophogenic potential. Affected areas of 11 patients with different forms of lupus erythematosus were treated with pimecrolimus 1% cream under semiocclusive conditions twice daily for 3 weeks. Skin involvement before and after therapy was assessed by means of a clinical score. In all patients, significant regression of skin lesions was observed after therapy (P <.001). This was an open and uncontrolled study on a limited number of cases. We suggest that pimecrolimus 1% cream could be an efficacious and safe treatment option for cutaneous lupus erythematosus.

Publication types

  • Clinical Trial

MeSH terms

  • Administration, Cutaneous
  • Adolescent
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Child
  • Facial Dermatoses / drug therapy
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Lupus Erythematosus, Cutaneous / drug therapy*
  • Lupus Erythematosus, Discoid / drug therapy*
  • Lupus Erythematosus, Systemic / drug therapy*
  • Male
  • Middle Aged
  • Patient Acceptance of Health Care
  • Tacrolimus / administration & dosage
  • Tacrolimus / analogs & derivatives*
  • Tacrolimus / therapeutic use*
  • Treatment Outcome


  • Anti-Inflammatory Agents, Non-Steroidal
  • Immunosuppressive Agents
  • pimecrolimus
  • Tacrolimus